James H Flory1, Sean Hennessy2, Clifford J Bailey3, Silvio E Inzucchi4. 1. Memorial Sloan-Kettering Cancer Center, New York, NY floryj@mskcc.org. 2. University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. School of Life and Health Sciences, Aston University, Birmingham, U.K. 4. Yale School of Medicine, New Haven, CT.
Abstract
OBJECTIVE: In 2016, the U.S. Food and Drug Administration (FDA) revised metformin's label to permit use in patients with mild-moderate chronic kidney disease. We sought to determine whether this change was associated with increased reports of metformin-associated lactic acidosis (MALA) to the FDA's Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Publicly available FAERS reports were analyzed. RESULTS: MALA reports increased from 521 in 2015 to 1,939 in 2018. After restriction to U.S. reports, absolute and relative increase in MALA reports was less, from 111 to 243. The proportionate reporting ratio (PRR), a measure adjusted for rates of other adverse event reports, was stable. CONCLUSIONS: The increased reports deserve attention, but the PRR's stability and FAERS's known limitations, including lack of a denominator or control group, do not permit the conclusion that U.S. MALA rates have increased. Further study with more robust data sources is needed.
OBJECTIVE: In 2016, the U.S. Food and Drug Administration (FDA) revised metformin's label to permit use in patients with mild-moderate chronic kidney disease. We sought to determine whether this change was associated with increased reports of metformin-associated lactic acidosis (MALA) to the FDA's Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Publicly available FAERS reports were analyzed. RESULTS: MALA reports increased from 521 in 2015 to 1,939 in 2018. After restriction to U.S. reports, absolute and relative increase in MALA reports was less, from 111 to 243. The proportionate reporting ratio (PRR), a measure adjusted for rates of other adverse event reports, was stable. CONCLUSIONS: The increased reports deserve attention, but the PRR's stability and FAERS's known limitations, including lack of a denominator or control group, do not permit the conclusion that U.S. MALA rates have increased. Further study with more robust data sources is needed.
Authors: Zachary A Marcum; Christopher W Forsberg; Kathryn P Moore; Ian H de Boer; Nicholas L Smith; Edward J Boyko; James S Floyd Journal: J Gen Intern Med Date: 2017-11-27 Impact factor: 5.128
Authors: Jean-Daniel Lalau; Farshad Kajbaf; Youssef Bennis; Anne-Sophie Hurtel-Lemaire; Frans Belpaire; Marc E De Broe Journal: Diabetes Care Date: 2018-01-05 Impact factor: 19.112
Authors: David M Charytan; Scott D Solomon; Peter Ivanovich; Giuseppe Remuzzi; Mark E Cooper; Janet B McGill; Hans-Henrik Parving; Patrick Parfrey; Ajay K Singh; Emmanuel A Burdmann; Andrew S Levey; Kai-Uwe Eckardt; John J V McMurray; Larry A Weinrauch; Jiankang Liu; Brian Claggett; Eldrin F Lewis; Marc A Pfeffer Journal: Diabetes Obes Metab Date: 2019-03-04 Impact factor: 6.577
Authors: Benjamin Lazarus; Aozhou Wu; Jung-Im Shin; Yingying Sang; G Caleb Alexander; Alex Secora; Lesley A Inker; Josef Coresh; Alex R Chang; Morgan E Grams Journal: JAMA Intern Med Date: 2018-07-01 Impact factor: 21.873
Authors: Carlos A Alvarez; Ethan A Halm; Mary Jo V Pugh; Darren K McGuire; Sean Hennessy; Richard T Miller; Ildiko Lingvay; Scott M Vouri; Andrew R Zullo; Hui Yang; Matt Chansard; Eric M Mortensen Journal: Endocrinol Diabetes Metab Date: 2020-07-17